tiprankstipranks
AstraZeneca PLC (AZN)
NYSE:AZN
US Market
AZN
AstraZeneca
RESEARCH TOOLSreports

AstraZeneca (AZN) Stock Forecast & Price Target

369 Followers
See the Price Targets and Ratings of:

AZN Analyst Ratings

Strong Buy
16Ratings
Strong Buy
13 Buy
2 Hold
1 Sell
Based on 16 analysts giving stock ratings to
AstraZeneca
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AZN Stock 12 Month Forecast

Average Price Target

$217.29
▲(6.37% Upside)
Based on 16 Wall Street analysts offering 12 month price targets for AstraZeneca in the last 3 months. The average price target is $217.29 with a high forecast of $271.83 and a low forecast of $149.84. The average price target represents a 6.37% change from the last price of $204.27.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"136":"$136","170":"$170","204":"$204","238":"$238","272":"$272"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":271.827335,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$271.83</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":217.2880311043,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$217.29</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":149.836531,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$149.84</span>\n  </div></div>","useHTML":true}}],"tickPositions":[136,170,204,238,272],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Jul<br/>2025","6":"Oct<br/>2025","9":"Jan<br/>2026","12":"Apr<br/>2026","25":"Apr<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,200.73,206.19902576923076,211.66805153846153,217.1370773076923,222.60610307692306,228.07512884615383,233.54415461538463,239.0131803846154,244.48220615384616,249.95123192307693,255.4202576923077,260.88928346153847,266.35830923076924,{"y":271.827335,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,200.73,202.00369470033075,203.27738940066152,204.55108410099228,205.82477880132308,207.09847350165384,208.3721682019846,209.64586290231537,210.91955760264614,212.1932523029769,213.4669470033077,214.74064170363846,216.01433640396922,{"y":217.2880311043,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,200.73,196.81511776923077,192.90023553846154,188.9853533076923,185.07047107692307,181.15558884615385,177.24070661538462,173.32582438461537,169.41094215384615,165.49605992307693,161.5811776923077,157.66629546153848,153.75141323076923,{"y":149.836531,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":145.565,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 68,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":138.204,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 61,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":140.042,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 51,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":137.3,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 57,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":144.956,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 55,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":159.453,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":160.864,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 45,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":161.225,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 53,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":178.474,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 50,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":173.674,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 40,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":186.45,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 5</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":203.73,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 64,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 7</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":200.73,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 56,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 6</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$271.83Average Price Target$217.29Lowest Price Target$149.84
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on AZN
Richard Vosser
J.P. Morgan
J.P. Morgan
$212.16
Buy
3.86%
Upside
Reiterated
04/07/26
J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
Morgan Stanley Analyst forecast on AZN
Sarita Kapila
Morgan Stanley
Morgan Stanley
$212.16→$218.79
Buy
7.11%
Upside
Reiterated
04/07/26
AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy RatingWe update our AZN model ahead of Q1’26 results and forecast Q1’26 group sales to come in ~1% above consensus (~7% YoY at CER), driven by Oncology (MSe +2% vs. cons.) and CVRM (+3% ahead of cons.). In Oncology, momentum remains strong, led by Imfinzi (MSe +4% ahead of cons.), Calquence (+4% ahead of cons.), and Enhertu (+10% ahead of cons.). In CVRM, we model Farxiga +5% ahead of street. Our Q1’26 EPS estimates are ~1% above consensus. We expect AZN to reiterate FY26 guidance for MSD-HSD% revenue growth and LDD% core EPS growth. Reflecting FX updates and recent positive pipeline developments (including tozorakimab in COPD and efzimfotase alfa in HPP), we raise our base case price target to £165/share and reiterate our Overweight rating. Our bull and bear cases increase by a similar magnitude.
Goldman Sachs Analyst forecast on AZN
Rajan Sharma
Goldman Sachs
Goldman Sachs
$218.73→$220.11
Buy
7.76%
Upside
Reiterated
04/02/26
AstraZeneca (AZN) Receives a Buy from Goldman Sachs
Bank of America Securities Analyst forecast on AZN
Sachin Jain
Bank of America Securities
Bank of America Securities
$218.79
Buy
7.11%
Upside
Reiterated
04/01/26
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
Barclays Analyst forecast on AZN
James Gordon CFA
Barclays
Barclays
$218.79
Buy
7.11%
Upside
Reiterated
03/31/26
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
Jefferies Analyst forecast on AZN
Michael Leuchten
Jefferies
Jefferies
$238.68
Buy
16.84%
Upside
Reiterated
03/31/26
Jefferies Sticks to Its Buy Rating for AstraZeneca (AZN)
Deutsche Bank Analyst forecast on AZN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$152.49
Sell
-25.35%
Downside
Reiterated
03/30/26
Deutsche Bank Reaffirms Their Sell Rating on AstraZeneca (AZN)
Citi Analyst forecast on AZN
Graham Parry
Citi
Citi
$225.42
Buy
10.35%
Upside
Reiterated
03/30/26
Citi Sticks to Its Buy Rating for AstraZeneca (AZN)
Guggenheim Analyst forecast on AZN
Seamus Fernandez
Guggenheim
Guggenheim
$212.16→$218.79
Buy
7.11%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on AZN
Steve Scala
TD Cowen
TD Cowen
$240
Buy
17.49%
Upside
Reiterated
03/18/26
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating
Bernstein Analyst forecast on AZN
Justin Smith
Bernstein
Bernstein
$14.1→$271.83
Buy
33.07%
Upside
Reiterated
03/18/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on AZN
Luisa Hector
Berenberg Bank
Berenberg Bank
$225.42
Buy
10.35%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
UBS Analyst forecast on AZN
Matthew Weston
UBS
UBS
$216.14→$233.37
Buy
14.25%
Upside
Reiterated
02/25/26
UBS Remains a Buy on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on AZN
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Kepler Capital Analyst forecast on AZN
David Evans
Kepler Capital
Kepler Capital
$149.84
Hold
-26.65%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
J.P. Morgan Analyst forecast on AZN
Richard Vosser
J.P. Morgan
J.P. Morgan
$212.16
Buy
3.86%
Upside
Reiterated
04/07/26
J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
Morgan Stanley Analyst forecast on AZN
Sarita Kapila
Morgan Stanley
Morgan Stanley
$212.16→$218.79
Buy
7.11%
Upside
Reiterated
04/07/26
AstraZeneca: Oncology and CVRM Momentum, Pipeline Progress, and FX Tailwinds Underpin Raised £165 Price Target and Buy RatingWe update our AZN model ahead of Q1’26 results and forecast Q1’26 group sales to come in ~1% above consensus (~7% YoY at CER), driven by Oncology (MSe +2% vs. cons.) and CVRM (+3% ahead of cons.). In Oncology, momentum remains strong, led by Imfinzi (MSe +4% ahead of cons.), Calquence (+4% ahead of cons.), and Enhertu (+10% ahead of cons.). In CVRM, we model Farxiga +5% ahead of street. Our Q1’26 EPS estimates are ~1% above consensus. We expect AZN to reiterate FY26 guidance for MSD-HSD% revenue growth and LDD% core EPS growth. Reflecting FX updates and recent positive pipeline developments (including tozorakimab in COPD and efzimfotase alfa in HPP), we raise our base case price target to £165/share and reiterate our Overweight rating. Our bull and bear cases increase by a similar magnitude.
Goldman Sachs Analyst forecast on AZN
Rajan Sharma
Goldman Sachs
Goldman Sachs
$218.73→$220.11
Buy
7.76%
Upside
Reiterated
04/02/26
AstraZeneca (AZN) Receives a Buy from Goldman Sachs
Bank of America Securities Analyst forecast on AZN
Sachin Jain
Bank of America Securities
Bank of America Securities
$218.79
Buy
7.11%
Upside
Reiterated
04/01/26
AstraZeneca: Buy Rating on Near‑Term Execution Strength and Undemanding Valuation Ahead of Pipeline‑Driven Re‑Rating
Barclays Analyst forecast on AZN
James Gordon CFA
Barclays
Barclays
$218.79
Buy
7.11%
Upside
Reiterated
03/31/26
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
Jefferies Analyst forecast on AZN
Michael Leuchten
Jefferies
Jefferies
$238.68
Buy
16.84%
Upside
Reiterated
03/31/26
Jefferies Sticks to Its Buy Rating for AstraZeneca (AZN)
Deutsche Bank Analyst forecast on AZN
Emmanuel Papadakis
Deutsche Bank
Deutsche Bank
$152.49
Sell
-25.35%
Downside
Reiterated
03/30/26
Deutsche Bank Reaffirms Their Sell Rating on AstraZeneca (AZN)
Citi Analyst forecast on AZN
Graham Parry
Citi
Citi
$225.42
Buy
10.35%
Upside
Reiterated
03/30/26
Citi Sticks to Its Buy Rating for AstraZeneca (AZN)
Guggenheim Analyst forecast on AZN
Seamus Fernandez
Guggenheim
Guggenheim
$212.16→$218.79
Buy
7.11%
Upside
Reiterated
03/29/26
Guggenheim Sticks to Its Buy Rating for AstraZeneca (AZN)
TD Cowen Analyst forecast on AZN
Steve Scala
TD Cowen
TD Cowen
$240
Buy
17.49%
Upside
Reiterated
03/18/26
AstraZeneca: Diversified Growth, Compelling Valuation, and Manageable Risks Support Buy Rating
Bernstein Analyst forecast on AZN
Justin Smith
Bernstein
Bernstein
$14.1→$271.83
Buy
33.07%
Upside
Reiterated
03/18/26
Bernstein Remains a Buy on AstraZeneca (AZN)
Berenberg Bank Analyst forecast on AZN
Luisa Hector
Berenberg Bank
Berenberg Bank
$225.42
Buy
10.35%
Upside
Assigned
03/16/26
AstraZeneca (AZN) Gets a Buy from Berenberg Bank
UBS Analyst forecast on AZN
Matthew Weston
UBS
UBS
$216.14→$233.37
Buy
14.25%
Upside
Reiterated
02/25/26
UBS Remains a Buy on AstraZeneca (AZN)
DZ BANK AG Analyst forecast on AZN
Elmar Kraus
DZ BANK AG
DZ BANK AG
―
Hold
―
Reiterated
02/12/26
DZ BANK AG Remains a Hold on AstraZeneca (AZN)
Kepler Capital Analyst forecast on AZN
David Evans
Kepler Capital
Kepler Capital
$149.84
Hold
-26.65%
Downside
Reiterated
02/10/26
AstraZeneca (AZN) Receives a Hold from Kepler Capital
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
xxx
xxx
xxx
xxx
xxx
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering AstraZeneca

3 Months
xxx
Success Rate
15/21 ratings generated profit
71%
Average Return
+4.16%
reiterated a xxx
 rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 3 Months would result in 71.43% of your transactions generating a profit, with an average return of +4.16% per trade.
1 Year
Matthew WestonUBS
Success Rate
36/38 ratings generated profit
95%
Average Return
+18.02%
reiterated a buy rating last month
Copying Matthew Weston's trades and holding each position for 1 Year would result in 94.74% of your transactions generating a profit, with an average return of +18.02% per trade.
2 Years
xxx
Success Rate
20/21 ratings generated profit
95%
Average Return
+27.80%
reiterated a xxx
 rating 23 days ago
Copying xxxxxxxxxxxxxxxxxx
 trades and holding each position for 2 Years would result in 95.24% of your transactions generating a profit, with an average return of +27.80% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AZN Analyst Recommendation Trends

Rating
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
Strong Buy
0
0
0
0
0
Buy
50
40
35
64
56
Hold
3
2
2
2
2
Sell
0
0
1
1
1
Strong Sell
6
5
4
6
5
total
59
47
42
73
64
In the current month, AZN has received 56 Buy Ratings, 2 Hold Ratings, and 6 Sell Ratings. AZN average Analyst price target in the past 3 months is 217.29.
Each month's total comprises the sum of three months' worth of ratings.

AZN Financial Forecast

AZN Earnings Forecast

Next quarter’s earnings estimate for AZN is $2.52 with a range of $2.40 to $2.77. The previous quarter’s EPS was $2.12. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s earnings estimate for AZN is $2.52 with a range of $2.40 to $2.77. The previous quarter’s EPS was $2.12. AZN beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Sales Forecast

Next quarter’s sales forecast for AZN is $14.83B with a range of $14.34B to $15.26B. The previous quarter’s sales results were $15.62B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.
Next quarter’s sales forecast for AZN is $14.83B with a range of $14.34B to $15.26B. The previous quarter’s sales results were $15.62B. AZN beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year AZN has Performed in-line its overall industry.

AZN Stock Forecast FAQ

What is AZN’s average 12-month price target, according to analysts?
Based on analyst ratings, AstraZeneca PLC’s 12-month average price target is 217.29.
    What is AZN’s upside potential, based on the analysts’ average price target?
    AstraZeneca PLC has 6.37% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is AZN a Buy, Sell or Hold?
          AstraZeneca PLC has a consensus rating of Strong Buy which is based on 13 buy ratings, 2 hold ratings and 1 sell ratings.
            What is AstraZeneca PLC’s price target?
            The average price target for AstraZeneca PLC is 217.29. This is based on 16 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $271.83 ,the lowest forecast is $149.84. The average price target represents 6.37% Increase from the current price of $204.27.
              What do analysts say about AstraZeneca PLC?
              AstraZeneca PLC’s analyst rating consensus is a Strong Buy. This is based on the ratings of 16 Wall Streets Analysts.
                How can I buy shares of AZN?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.